-
1 Comment
SomnoMed Limited is currently in a long term uptrend where the price is trading 11.4% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.4.
Finally, its free cash flow grew by 95.3% to $1M since the same quarter in the previous year.
Based on the above factors, SomnoMed Limited gets an overall score of 3/5.
| ISIN | AU000000SOM1 |
|---|---|
| Industry | Medical Devices |
| Sector | Healthcare |
| CurrencyCode | EUR |
| Exchange | F |
| Dividend Yield | 0.0% |
|---|---|
| Target Price | None |
| PE Ratio | None |
| Market Cap | 52M |
| Beta | 1.05 |
SomnoMed Limited, together with its subsidiaries, engages in the production and sale of devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific region. It offers SomnoDent, an oral appliance for obstructive sleep apnea; SomnoBrux, a dental guard for the treatment of teeth grinding damage; SomMorning Repositioner, which help return mandible back to its pre-treatment centric position; and SomTabs for cleaning oral devices. The company was incorporated in 1987 and is headquartered in Crows Nest, Australia.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for RJV.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
